Novo Nordisk's GLP-1 Victoza Off To A Good Start
This article was originally published in The Pink Sheet Daily
Executive Summary
New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.
You may also be interested in...
Riding High, Victoza Hopes To Gain Ground Over Popular DPP-4s With Label Change
FDA label now notes superior efficacy and greater weight loss for Novo Nordisk’s injectable GLP-1 receptor agonist Victoza vs. Mercks’ DPP-4 inhibitor Januvia. Superiority would be expected for a GLP-1, but label still has potential to encourage earlier use of the class.
Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
Once-a-day here to stay? With once-weekly taspoglutide just officially rejected by Roche and long-lasting Bydureon delayed on safety, Zealand CEO talks up the virtues of QD GLP-1 analogs.
Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
Once-a-day here to stay? With once-weekly taspoglutide just officially rejected by Roche and long-lasting Bydureon delayed on safety, Zealand CEO talks up the virtues of QD GLP-1 analogs.